CD29 extradomain-B antagonist (Bayer Schering)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameCD29 extradomain-B antagonist (Bayer Schering)
Drug Alias NameCD29 extradomain-B antagonist (Schering)MOR-3255MOR-3257
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAngiogenesis inhibitorsIntegrin beta-1 inhibitors
TargetsIntegrin beta-1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEurope
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBayer Schering Pharma AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBayer Schering Pharma AG
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A